Placeholder Banner

Programming Announced for 2017 BIO Investor Forum

August 15, 2017
The annual BIO Investor Forum is coming again to San Francisco October 17-18. Programming for the event was just announced and includes seasoned speakers from the venture capital world and leaders from biopharma. The annual conference explores global investment trends and opportunities in life sciences. Early and mid-stage private as well as emerging public companies poised for growth in 2018 are the focus of the event.

Two speakers are lined up for “Fireside Chats” which will occur each day at the noon hour. On Tuesday (Oct. 17) attendees will hear from Kristina Burow, a managing director with ARCH Venture Partners. ARCH looks for ways to create and develop pharmaceutical and ag-biotechnology companies.With advanced degrees in chemistry and business, Burow serves as a director on the boards of 11 different companies, including recent start-ups BlackThorn Therapeutics, UNITY Biotechnology, and Vir Biotechnology.

[caption id="attachment_26235" align="alignright" width="200"] Kristina Burow, Managing Director, ARCH Venture Partners[/caption]

On day two (Oct. 18), Richard Scheller, PhD, Chief Science Officer & Head of Therapeutics for 23andMe, will headline the Fireside Chat. Scheller leads his company’s therapeutics research group that focuses on the use of human genetic data as the starting point for identifying new therapies for both common and rare diseases. His strong academic background and long stint in the biotech industry will help inform a discussion about the treasure trove of information held in human genetic data and the implications of direct-to-consumer tests for specific genetic conditions.

[caption id="attachment_26240" align="alignright" width="200"] Richard Scheller, PhD, Chief Science Officer & Head of Therapeutics, 23andMe[/caption]

Now in its 16th year, the BIO Investor Forum’s therapeutic and business panels include these and other topics:

  • Bispecific approaches to cancer treatments

  • Bottlenecks in commercialization of medically promising basic research

  • Addressing antimicrobial resistance.

  • Cross-Pacific investment in the biopharma space

  • New funding rounds for early-stage biotechs

  • Focus on improving leadership diversity

  • PDUFA and the Trump Administration’s healthcare plans

Additional programming to keep attendees on their toes include the BIO SPARK Showcase, company presentations, the “Buzz of BIO” contest and the proprietary BIO One-on-One™ Partnering™.

Nearly 170 company presentations by senior-level executives are expected this year to spotlight their pipelines, R&D activities, and investment goals before an audience of public and private equity investors, research analysts, investment bankers and industry executives. The list of companies—updated regularly—is available on the website.

Visit BIO Investment Forum for complete details on the entire program.

A discounted rate for registration is being offered now through September 7th.

Advance media registration is now available for qualified reporters working full time for print, broadcast and web publications with valid press credentials.